期刊文献+

雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿对眼压的影响 被引量:9

下载PDF
导出
摘要 目的 :观察视网膜静脉阻塞(RVO)伴黄斑水肿患者行玻璃体腔注射雷珠单抗(Lucentis)后的早期眼压改变。方法:视网膜静脉阻塞患者51例51只眼,视网膜分支静脉阻塞34例,视网膜中央静脉阻塞17例。治疗前1h非接触式眼压计测量的基础眼压平均为(16.31±2.26)mm Hg。根据眼压将患者分为偏低组(<16.00mm Hg)18例、偏高组(≥16.00mm Hg)33例两组。均接受雷珠单抗玻璃体腔注射0.5mg(0.05m L)治疗。治疗后1天及1周测量眼压。以眼压>21mm Hg为眼压升高。对比分析治疗前后眼压变化。结果:治疗后1天眼压由治疗前平均(16.31±2.26)mm Hg升高至(18.93±5.09)mm Hg(P<0.01)。基础眼压偏高组、BRVO组、CRVO组与术前比较均差异有统计学意义(P<0.01)。11例(21.57%)患者眼压升高,均为基础眼压偏高组。BRVO有5例(14.71%),CRVO有6例(35.29%),两组比较差异有统计学意义(P<0.05)。眼压升高>5mm Hg 9例(17.65%),眼压升高>10mm Hg 3例(5.88%)。治疗后1周平均眼压为(16.50±2.54)mm Hg,与治疗前比较差异无统计学意义(P>0.05)。结论:基础眼压偏高的患者更容易发生术后眼压增高。CRVO患者比BRVO患者更容易发生一过性眼压升高。
出处 《交通医学》 2015年第2期154-156,共3页 Medical Journal of Communications
  • 相关文献

参考文献12

  • 1Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions [ J ]. Ophthalmology, 2008,115 (10) : e47-e54.
  • 2Singer MA,Awh CC,Sadda SV,et al. HORIZON: an Open-Label extension trial of ranibizumab for choroidal neovascu- larization secondary to Age-Related macular degeneration [ J ]. Ophthalmology, 2012, 119 (6) : 1175-1183.
  • 3Brown DM,Campochiaro PA,Bhisitkul RB,et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-Month outcomes of a phase III study[J]. Ophthalmology,2011,118(8): 1594-1602.
  • 4Campochiaro PA, Brown DM, Awh CC,et al. Sustained bene- fits from ranibizumab for macular edema following central retinal vein occlusion: twel'4e-month outcomes of a phase III study[ J ]. Ophthalmology, 20l 1,118(10) : 2041-2049.
  • 5Schmucker C,Ehlken C,Agostini HT, et al.A safety review and meta-analyses of bevacizumab and ranibizumab:off-la- bel versus goldstandard[ J ]. PLoS One, 2012,7 (8) : e42701.
  • 6Lemos-Reis R,Moreira-Goncalves N, Melo AB, et al. Imme- diate effect of intravitreal injection of bevacizumab on in- traocular pressure [ J ]. Clin Ophthalmol, 2014,8 (8) : 1383 - 1388.
  • 7Kim JE, Mantravadi AV, I-Iur EY,et al. Short-term Intraocu- lar Pressure Changes Immediately After Intravitreal Injec- tions of Anti-Vascular Endothelial Growth Factor Agents [ J ]. Am J Ophthalmol, 2008,146(6 ) : 930-934.
  • 8Falkenstein IA,Cheng L, Freeman WR. Changes of intraocu- lar pressure after intravitreal injection of bevacizumab (avastin) [J]. Retina. 2007,27 ( 8 ) : 1044-1047.
  • 9Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamci- nolone acetonide and intraocular pressure[J]. Am J Oph- thalmol, 2004,138(5 ) : 740-743.
  • 10Brown DM, Campochiaro PA, Singh RP,et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study [ J ]. Ophthalmology, 2010,117(6) : 1124-1133.el.

同被引文献53

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部